Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q3 EPS of ($0.61), $0.20 worse than the analyst estimate of ($0.41).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.